News Releases

WESTON, Fla., March 14, 2018 /PRNewswire/ -- Cantex Pharmaceuticals, Inc. ("Cantex"), a clinical stage biopharmaceutical company developing proprietary pharmaceuticals for the treatment of cancer and other life-threatening disorders, today announced its Chief Executive Officer, Stephen Marcus, M.D., will present at the upcoming Sachs BioCapital USA Forum and the 25^th Annual Future Leaders in the Biotech Industry Conference.

Dr. Marcus will present Cantex's rapidly advancing drug development pipeline, highlighted by CX-01 and Dicopp™. CX-01 is currently being evaluated in Phase II clinical trials for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), while Dicopp™ is in a Phase II clinical trial for recurrent glioblastoma and in a separate investigator-initiated clinical trial for metastatic castration-resistant prostate cancer.

Details of Cantex's presentations are as follows:

About Cantex Pharmaceuticals, Inc.
Cantex is a clinical stage biopharmaceutical company focused on developing and commercializing proprietary compounds that enhance the efficacy and safety of the treatment of cancer and other life-threatening disorders. Cantex's product candidate, CX-01, is a multi-targeted new chemical entity in development for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Cantex's other clinical stage product, Dicopp™, a proprietary combination of disulfiram + copper, is currently in clinical trials for recurrent glioblastoma and metastatic castration-resistant prostate cancer.  For more information, please visit www.cantex.com.

SOURCE Cantex Pharmaceuticals, Inc.